静脉注射托西利祖马布与皮下注射托西利祖马布在耐火性脑膜炎中的比较有效性:一个回顾性分析
Mathilde Leclercq1, Robin Jacquot2, Camille Charbonnier3
1Univ Rouen Normandie, Inserm U1234, CHU Rouen, Department of Internal Medicine, F-76000 Rouen, France.
Ophthalmology
|May 21, 2025
概括
静脉注射托西利祖马布 (IV TCZ) 可能比皮下TCZ (SC TCZ) 更快地解决乌维性斑点. 这两种治疗方法在非传染性脑膜炎的长期疗效和安全性表现相似.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 非传染性脑膜炎是导致视力丧失的重要原因.
- 托西利祖马布 (TCZ) 是一种用于治疗非传染性脑膜炎的交联素-6受体抑制剂.
- 为了优化治疗策略,对TCZ静脉注射 (IV) 和皮下注射 (SC) 的比较至关重要.
研究的目的:
- 为了比较IV TCZ与SC TCZ在治疗非传染性中间,后部和面膜炎的疗效和安全性.
- 为了评估黄斑的分辨率,视力敏度,疾病活动和两种药物注射途径之间的不良事件.
主要方法:
- 多中心,回顾性,观察性研究,包括136名患有非传染性脑膜炎的成年患者.
- 患者接受了IV TCZ (8 mg/kg/4周) 或SC TCZ (162 mg/周).
- 评估的结果包括6个月后黄斑的解决,最佳校正的视力敏度 (BCVA),疾病不活性,治疗成功和不良事件.
主要成果:
- 与SC TCZ (p=0.01) 相比,接受IV TCZ的患者中,在6个月内获得黄斑胀解消的比例较高 (p=0.01).
- 12个月后,IV TCZ使用时,BCVA的增益更大.
- 在12个月后,IV和SC TCZ组之间的疾病不活性和治疗成功率相似 (分别为p=0.80和p=0.99).
- 到复发或导致停药的严重不良事件的中位时间在各组之间没有显著差异.
结论:
- 静脉注射托西利祖马布与皮下注射相比,可能会更快地解决乌维性斑点.
- 无论是IV还是SC TCZ,在治疗非传染性脑膜炎方面,长期有效性和安全性都相当.
- 需要进一步的前性研究来证实这些发现.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...